Cargando…

Apoptosis and Molecular Targeting Therapy in Cancer

Apoptosis is the programmed cell death which maintains the healthy survival/death balance in metazoan cells. Defect in apoptosis can cause cancer or autoimmunity, while enhanced apoptosis may cause degenerative diseases. The apoptotic signals contribute into safeguarding the genomic integrity while...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassan, Mohamed, Watari, Hidemichi, AbuAlmaaty, Ali, Ohba, Yusuke, Sakuragi, Noriaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075070/
https://www.ncbi.nlm.nih.gov/pubmed/25013758
http://dx.doi.org/10.1155/2014/150845
_version_ 1782323287185948672
author Hassan, Mohamed
Watari, Hidemichi
AbuAlmaaty, Ali
Ohba, Yusuke
Sakuragi, Noriaki
author_facet Hassan, Mohamed
Watari, Hidemichi
AbuAlmaaty, Ali
Ohba, Yusuke
Sakuragi, Noriaki
author_sort Hassan, Mohamed
collection PubMed
description Apoptosis is the programmed cell death which maintains the healthy survival/death balance in metazoan cells. Defect in apoptosis can cause cancer or autoimmunity, while enhanced apoptosis may cause degenerative diseases. The apoptotic signals contribute into safeguarding the genomic integrity while defective apoptosis may promote carcinogenesis. The apoptotic signals are complicated and they are regulated at several levels. The signals of carcinogenesis modulate the central control points of the apoptotic pathways, including inhibitor of apoptosis (IAP) proteins and FLICE-inhibitory protein (c-FLIP). The tumor cells may use some of several molecular mechanisms to suppress apoptosis and acquire resistance to apoptotic agents, for example, by the expression of antiapoptotic proteins such as Bcl-2 or by the downregulation or mutation of proapoptotic proteins such as BAX. In this review, we provide the main regulatory molecules that govern the main basic mechanisms, extrinsic and intrinsic, of apoptosis in normal cells. We discuss how carcinogenesis could be developed via defective apoptotic pathways or their convergence. We listed some molecules which could be targeted to stimulate apoptosis in different cancers. Together, we briefly discuss the development of some promising cancer treatment strategies which target apoptotic inhibitors including Bcl-2 family proteins, IAPs, and c-FLIP for apoptosis induction.
format Online
Article
Text
id pubmed-4075070
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-40750702014-07-10 Apoptosis and Molecular Targeting Therapy in Cancer Hassan, Mohamed Watari, Hidemichi AbuAlmaaty, Ali Ohba, Yusuke Sakuragi, Noriaki Biomed Res Int Review Article Apoptosis is the programmed cell death which maintains the healthy survival/death balance in metazoan cells. Defect in apoptosis can cause cancer or autoimmunity, while enhanced apoptosis may cause degenerative diseases. The apoptotic signals contribute into safeguarding the genomic integrity while defective apoptosis may promote carcinogenesis. The apoptotic signals are complicated and they are regulated at several levels. The signals of carcinogenesis modulate the central control points of the apoptotic pathways, including inhibitor of apoptosis (IAP) proteins and FLICE-inhibitory protein (c-FLIP). The tumor cells may use some of several molecular mechanisms to suppress apoptosis and acquire resistance to apoptotic agents, for example, by the expression of antiapoptotic proteins such as Bcl-2 or by the downregulation or mutation of proapoptotic proteins such as BAX. In this review, we provide the main regulatory molecules that govern the main basic mechanisms, extrinsic and intrinsic, of apoptosis in normal cells. We discuss how carcinogenesis could be developed via defective apoptotic pathways or their convergence. We listed some molecules which could be targeted to stimulate apoptosis in different cancers. Together, we briefly discuss the development of some promising cancer treatment strategies which target apoptotic inhibitors including Bcl-2 family proteins, IAPs, and c-FLIP for apoptosis induction. Hindawi Publishing Corporation 2014 2014-06-12 /pmc/articles/PMC4075070/ /pubmed/25013758 http://dx.doi.org/10.1155/2014/150845 Text en Copyright © 2014 Mohamed Hassan et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Hassan, Mohamed
Watari, Hidemichi
AbuAlmaaty, Ali
Ohba, Yusuke
Sakuragi, Noriaki
Apoptosis and Molecular Targeting Therapy in Cancer
title Apoptosis and Molecular Targeting Therapy in Cancer
title_full Apoptosis and Molecular Targeting Therapy in Cancer
title_fullStr Apoptosis and Molecular Targeting Therapy in Cancer
title_full_unstemmed Apoptosis and Molecular Targeting Therapy in Cancer
title_short Apoptosis and Molecular Targeting Therapy in Cancer
title_sort apoptosis and molecular targeting therapy in cancer
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075070/
https://www.ncbi.nlm.nih.gov/pubmed/25013758
http://dx.doi.org/10.1155/2014/150845
work_keys_str_mv AT hassanmohamed apoptosisandmoleculartargetingtherapyincancer
AT watarihidemichi apoptosisandmoleculartargetingtherapyincancer
AT abualmaatyali apoptosisandmoleculartargetingtherapyincancer
AT ohbayusuke apoptosisandmoleculartargetingtherapyincancer
AT sakuraginoriaki apoptosisandmoleculartargetingtherapyincancer